过表达BTG2增强人肺腺癌细胞的辐射敏感性

在肺癌类型中,肺腺癌占大多数,其总体生存率差,BTG2是抗增殖基因家族的一员,属于BTG/TOB家族。许多研究表明,B细胞易位基因2(BTG2)多种类型的肿瘤中存在异常表达,但其在肺腺癌放疗敏感性中发挥的调控作用尚不明确。本研究通过肺腺癌组织样本及在线数据库,探究BTG2在肺腺癌患者中的表达水平及其表达与临床预后之间的相关性,结果提示在具有放疗抗性的肺腺癌患者中,BTG2的表达水平显著降低,且在肺腺癌细胞系中,BTG2能对放疗产生响应,其在肺腺癌患者中的低表达状态与不良的预后相关(P＜0.05);在人肺腺癌A549和H1299细胞系中转染过表达BTG2(OE-BTG2)慢病毒,通过克隆形成检测过表达BTG2对肺腺癌细胞系的辐射敏感性的影响,实验证实过表达BTG2可显著增强A549和H1299细胞系的辐射敏感性(P＜0.05);并进一步通过WB、免疫组化检测BTG2及凋亡相关蛋白BAX的表达水平,结果证实:过表达BTG2可显著增加A549和H1299细胞辐射后的凋亡水平。最后通过裸鼠成瘤试验检测BTG2在活体中对肺腺癌辐射敏感性的影响,结果提示:在动物实验中,过表达BTG2可显著增强肺腺癌的辐射敏感性(P＜0.05)及增加辐射后BAX的表达水平。综上所述,BTG2在肺腺癌组织中处于低表达状态,并且与不良的临床预后紧密相关,过表达BTG2可促进凋亡过程,增加人肺腺癌细胞系的辐射敏感性,能为克服肺腺癌的辐射抗性提供新的靶点。     

沙棘总黄酮抑制肺癌A549增殖和迁移作用及机理

为探究三种沙棘总黄酮(TFH)对非小细胞肺癌A549细胞增殖及迁移的影响,并探讨其分子作用机制,选择不同浓度的西藏沙棘(Hippophae tibetana Schlecht)、中国沙棘(H.rhamnoides L.subsp.sinensis Rousi)、肋果沙棘(H.neurocarpa)总黄酮作用于A549细胞。通过MTT检测细胞相对活力,平板克隆形成实验及软琼脂克隆形成实验检测细胞克隆形成能力,流式细胞仪AnnexinV/PI双染法检测细胞凋亡比例。选择效果最佳的西藏沙棘总黄酮应用细胞划痕实验及Transwell实验分析该化合物对肺癌细胞迁移侵袭能力的影响。Western blot检测MMP9、E-cadherin等侵袭迁移相关蛋白表达。敲低E-cadherin基因检测沙棘总黄酮对细胞迁移能力的影响。结果显示,三种沙棘总黄酮均对A549细胞系具有增殖抑制作用,抑制作用依次为:西藏沙棘中国沙棘肋果沙棘。西藏沙棘总黄酮可显著性抑制非小细胞肺癌A549细胞侵袭迁移能力(P0.05)。实验组中MMP9、MMP2、TGF-β、N-cadherin表达水平显著降低,E-cadherin表达水平上调。我们发现在A549细胞中敲低E-cadherin,西藏沙棘总黄酮可逆转迁移增加。以上研究表明西藏沙棘总黄酮对肺癌A549增殖抑制作用具有明显的优势,且西藏沙棘总黄酮可明显抑制肺癌A549细胞的侵袭迁移能力,并可能与下调细胞中的TGF-β抑制MMP9表达并阻止肺癌EMT有关。     

PARP15在肺腺癌中的表达及其对肺腺癌细胞生长、凋亡的影响

该文研究了PARP15过表达在肺腺癌中的临床意义及其对肺腺癌细胞生长、凋亡的影响。利用UALCAN和GEPIA数据库比对PARP15基因在肺腺癌组织和正常组织中的表达水平,利用GEPIA数据库分析PARP15基因对肺腺癌患者预后生存的影响。构建核心质粒pCDH-PARP15,通过慢病毒包装及感染的方法在人肺腺癌细胞系A549和H1299中获得PARP15过表达稳定株,用Western blot鉴定PARP15过表达情况。采用CCK-8、克隆形成实验检测过表达PARP15对A549和H1299细胞生长的影响,流式细胞仪检测PARP15对A549和H1299细胞凋亡和细胞周期的影响。PARP15基因在肺腺癌组织中的表达水平均低于正常组织(P<0.05),且PARP15基因的表达水平与肺腺癌患者的良好预后呈正相关(P=0.003 6)。过表达PARP15抑制肺腺癌细胞的生长(P<0.05),并诱导细胞凋亡(P<0.05),但对细胞周期没有显著影响。PARP15可通过诱导肺腺癌细胞凋亡从而发挥抑制其生长的作用。     

TRBP2基因过表达对肺腺癌A549细胞增殖、迁移及侵袭的影响及可能机制

该文探讨了TAR RNA结合蛋白2(TAR RNA binding protein 2,TRBP2)基因对肺腺癌A549细胞增殖、迁移及侵袭的影响及可能机制。构建TRBP2慢病毒过表达载体,以不同感染复数(MOI)感染A549细胞,根据绿色荧光强度选择最适MOI值。荧光定量PCR(FQ-PCR)检测TRBP2、MMP-2(matrix metalloproteinase-2)、PKR(double-stranded RNA-dependent protein kinase)m RNA的表达量。免疫蛋白印记(Western blot)法检测TRBP2、MMP-2、PKR、p-PKR的表达。采用MTT法、平板克隆实验检测TRBP2基因对A549细胞增殖的影响,Transwell迁移及侵袭实验检测细胞迁移和侵袭能力,黏附实验检测同种细胞和异种细胞间黏附情况。结果发现,成功构建了TRBP2基因过表达的A549细胞株,与空载体组和对照组比较,TRBP2基因过表达组细胞侵袭、迁移能力明显增强(P0.05),同种细胞间黏附力减弱(P0.05)而异种细胞间黏附力增强(P0.05),增殖速度加快(P0.05)及克隆形成率增加(P0.05)。此外,MMP-2、TRBP2蛋白及m RNA表达量明显升高(P0.05);p-PKR蛋白表达量降低(P0.05);PKR蛋白及m RNA表达量无差异。对照组与空载体组之间比较,以上各项指标均没有明显差异(P0.05)。该研究表明,过表达TRBP2基因可能通过促进MMP-2的表达同时抑制PKR磷酸化来促进肺腺癌A549细胞增殖、迁移及侵袭。     

lncRNA BLACAT1通过抑制miR-374b-5p促进非小细胞肺癌细胞增殖和转移

目的:研究长链非编码RNA BLACAT1在非小细胞肺癌发生和转移过程中的作用机制。方法:starBase软件分析TCGA数据库中肺腺癌及肺鳞癌与癌旁组织之间BLACAT1表达差异;qRT-PCR检测人非小细胞肺癌细胞A549、HCC827、NCI-H1299、NCI-H23和正常肺上皮细胞BEAS-2B中BLACAT1的转录水平差异,筛选BLACAT1高表达非小细胞肺癌细胞系;CCK-8检测BLACAT1对非小细胞肺癌细胞增殖能力的影响;Transwell检测BLACAT1对非小细胞肺癌细胞迁移和侵袭能力的影响;starBase软件预测BLACAT1作用的miRNA,采用qRT-PCR验证敲低BLACAT1对预测miRNA表达的影响,筛选与BLACAT1相互作用的miRNA,双萤光素酶报告基因实验验证结果;CCK-8检测BLACAT1/miR-374b-5p对非小细胞肺癌细胞增殖能力的影响;Transwell检测BLACAT1/miR-374b-5p对非小细胞肺癌细胞迁移和侵袭能力的影响;Western印迹检测非小细胞肺癌细胞转移相关基因的蛋白表达水平。结果:肺腺癌及肺鳞癌组织中BLACAT1表达量显著高于癌旁组织;非小细胞肺癌细胞A549的BLACAT1表达量最高;敲低BLACAT1降低A549细胞活力、迁移和侵袭能力;BLACAT1作为海绵吸附miR-374b-5p;敲低BLACAT1增加miR-374b-5p的表达,抑制非小细胞肺癌细胞增殖、迁移和侵袭。结论:BLACAT1通过抑制miR-374b-5p促进非小细胞肺癌细胞增殖和转移。     

HSP70在放线菌素D所致肺腺癌细胞增殖抑制和凋亡中的作用

为探讨热休克蛋白70(heatshockprotein70,HSP70)在肺腺癌中的表达及其作用,首先采用免疫印迹检测经临床支纤镜确诊并行手术切除的肺腺癌组织标本中HSP70的表达,结果显示在癌旁正常组织中HSP70的表达量显著低于其在癌组织中的表达量.其次,采用HSP70反义寡核苷酸阻断A549细胞中HSP70表达后,经MTT和Hoechst33258检测发现,HSP70下调能显著促进放线菌素D(actinomycinD,ActD)所致的A549细胞增殖抑制及凋亡,反义寡核苷酸处理组与正义或随机寡核苷酸处理组比较P值均小于0.05.进一步构建HSP70真核重组质粒并瞬时转染A549细胞后,能显著增加A549细胞中HSP70表达,同时采用MTT和流式细胞术及基因组DNA琼脂糖凝胶电泳检测发现,HSP70过表达能显著抵消ActD所致细胞增殖抑制及凋亡,转染HSP70重组质粒组与转染空载体组相比P值小于0.05.上述结果提示,HSP70在肺腺癌组织中高表达,高表达的HSP70在降低肺腺癌细胞对ActD的敏感性及促进癌细胞增殖与抑制凋亡等方面发挥了重要作用.     

建立稳定敲减TNIK表达的A549细胞系及对其初步分析

TNIK(TRAF2 and NCK interacting kinase)属丝氨酸/苏氨酸激酶家族成员,在多种生理及病理过程中起关键作用。研究发现,TNIK在肺鳞癌组织中高表达且可驱动癌细胞增殖等恶性表型,但其在肺腺癌中的作用仍未知。该研究在构建稳定敲减TNIK表达的肺腺癌A549细胞后,流式细胞术检测发现稳定敲减TNIK阻滞细胞周期进程并诱发凋亡,细胞增殖及运动实验证明肺癌细胞增殖与迁移能力被显著抑制。进一步通过免疫荧光染色分析发现,稳定敲减TNIK表达后会诱导细胞微丝骨架排列紊乱并抑制黏着斑动态周转(组装/解聚)。综上研究结果表明,肺腺癌细胞中TNIK可能通过调节微丝骨架排列,从而影响黏着斑动态周转最终控制细胞增殖及迁移运动;推测肺腺癌细胞中高表达的TNIK可能通过调控细胞微丝骨架系统以维持癌细胞恶性表型。     

硫利达嗪通过线粒体应激信号通路诱导肺腺癌细胞发生免疫原性死亡

硫利达嗪作为吩噻嗪类抗精神病类药物,具有诱导肿瘤发生免疫原性死亡(ICD)、激活特异性免疫反应的潜力。本研究利用A549和H1299细胞探讨了硫利达嗪诱导肺腺癌细胞免疫原性死亡及其分子机制。将不同浓度的硫利达嗪与A549和H1299细胞共孵育24 h后,利用四甲基偶氮唑蓝(MTT)法检测细胞的存活及生长情况,利用流式细胞术分析细胞凋亡率,利用ATP检测试剂盒检测细胞上清中的ATP含量,利用免疫荧光法检测细胞表面钙网蛋白(CRT)的表达,利用蛋白质印迹(Western blot)法检测凋亡相关蛋白裂解的含半胱氨酸的天冬氨酸蛋白水解酶3(Cleaved caspase 3)、B淋巴细胞瘤-2(Bcl-2)、Bcl-2相关X蛋白(Bax)、细胞色素C(Cyt C)的表达水平。结果表明,硫利达嗪能够显著抑制A549和H1299细胞的增殖,促进细胞凋亡,细胞增殖抑制及凋亡呈浓度依赖性。ATP分泌量增加及细胞表面CRT的表达水平上调,表明上述细胞发生了免疫原性死亡。而Bcl-2表达水平下降,Bax和Cyt C以及Cleaved caspase 3表达水平上调,进一步证明了硫利达嗪可诱导肿瘤细胞凋亡。上述结果表明,硫利达嗪可通过线粒体应激信号通路诱导肺腺癌细胞发生免疫原性死亡,从而抑制肿瘤细胞的增殖。     

STAMBPL1 promotes the progression of lung adenocarcinoma by inhibiting DHRS2 expression

BackgroundLung cancer is responsible for the majority of cancer deaths in the world. We found a significant increase of STAMBPL1 expression in lung adenocarcinoma (LUAD) tissues and cells. However, its mechanism has not been clarified.MethodsLUAD tissues and adjacent normal tissues were collected from 62 patients treated in the First Affiliated Hospital of Wenzhou Medical University from August 2018 to August 2021. In vivo, the clinical data and STAMBPL1 expression of 62 patients with LUAD were analyzed by qPCR. In vitro, cell experiments were carried out after STAMBPL1 knockdown in A549 and H1299 cells to determine cell growth, migration rate, evasiveness, colony-forming ability, and apoptosis. Gene sequencing was used to explore the expression of various genes in A549 and H1299 cells to verify that DHRS2 was up-regulated after STAMBPL1 knockdown; cell experiments further detected the role of the DHRS2 gene after DHRS2 overexpression in A549 and H1299 cells. A rescue experiment was conducted to certify that STAMBPL1 promotes NSCLC progression by regulating DHRS2 expression.ResultsAfter STAMBPL1 knockdown by siRNA. Migration, invasion, colony formation, and proliferation of siRNA groups were suppressed than those of NC groups in A549 and H1299 cells, while the cell apoptosis rate of siRNA groups increased significantly. By using gene-sequence analysis, we found that the expression level of the DHRS2 gene was up-regulated in STAMBPL1 siRNA groups, compared with STAMBPL1 NC (negative control) groups in A549 and H1299, which was verified by qPCR and WB. Further experiments showed that the DHRS2 OE group was suppressed in cell proliferation, migration, and invasion in the A549 and H1299 cell lines compared to the DHRS2 NC group, while DHRS2 OE group was significantly enhanced in the cell apoptosis in the A549 and H1299 cell lines. According to the rescue experiment, cell proliferation, migration, and invasion of the STAMBPL1 SI+DHRS2 SI group were enhanced compared with the STAMBPL1 SI+DHRS2 NC group in A549 and H1299 cells, while the STAMBPL1 SI+DHRS2 OE group were further decreased.ConclusionsThe expression of STAMBPL1 mRNA is significantly up-regulated in LUAD, promoting the progression of LUAD by down-regulating the expression of DHRS2 and acting as a potential biomarker of LUAD.     

Digoxin exerts anticancer activity on human nonsmall cell lung cancer cells by blocking PI3K/Akt pathway

Lung cancer remains the leading cause of cancer mortality because of its metastatic potential and high malignancy. The discovery of new applications for old drugs is a shortcut for cancer therapy. We recently investigated the antitumor effect of digoxin, a well-established drug for treating heart failure, against nonsmall cell lung cancer A549 and H1299 cells. Digoxin inhibited the proliferation and colony-forming ability of the two cell lines and arrested the cell cycle at the G0/G1 phase in A549 cells and the G2/M phase in H1299 cells. Mitochondria-mediated apoptosis was induced in A549 cells but not in H1299 cells after treatment with digoxin. Moreover, digoxin inhibited the migration, invasion, adhesion and epithelial–mesenchymal transition of A549 and H1299 cells. Autophagy was induced in both cell lines after treatment with digoxin, with an increase in autophagosome foci. In addition, digoxin inhibited the phosphorylation of Akt, mTOR and p70S6K, signaling molecules of the PI3K/Akt pathway that are known to be involved in tumor cell survival, proliferation, metastasis and autophagy. Our findings suggest that digoxin has the potential to be used for therapy for human nonsmall cell lung cancer, but further evidence is required.     

X-ray irradiation altered chemosensitivity of a p53-null non-small cell lung cancer cell line

Radiotherapy is an effective approach to treating many types of cancer. Recent progress in radiotherapy technology, such as intensity-modulated radiation therapy (IMRT) and three-dimensional (3D) radiotherapy, allow precise energy transfer to the tumor, which has improved local control rates. However, the emergence of tolerant cells during or after radiotherapy remains problematic. In the present study, we first established a cell population from H1299, the p53-null non-small cell lung cancer cell line, by 10 Gy irradiation using 6 MV X-rays. The radio- and chemosensitivity of this cell population (referred to as H1299-IR) was determined using colony formation analyses and MTS assays. Compared with the parental cell line, the radiosensitivity of H1299-IR was apparently the same. H1299 and H1299-IR were both more radio tolerant than the A549 cell line. However, H1299-IR became significantly more sensitive to cisplatin, an antitumor agent. After exposure to 25 mug/ml cisplatin for 2 h, parental cells steadily grew during the MTS assay, whereas the sensitivity of H1299-IR cells doubled both at 24 and 48 h. Microarray analysis of over 30,000 H1299-IR genes (Agilent Technology) revealed that 12 and 15 genes were up- (> 2.0) and down- (< 2.0) regulated, respectively. Rad51d (homologous recombination repair protein) gene was down-regulated 2.8-fold, whereas matrix metalloproteinase 1 (collagenase-1) gene was up-regulated 4.4-fold. These results indicated that some p53-null non-small cell lung cancers could be successfully treated when X-ray radiotherapy was administered with subsequent or concurrent cisplatin chemotherapy.     

ARHGAP9 knockdown promotes lung adenocarcinoma metastasis by activating Wnt/β-catenin signaling pathway via suppressing DKK2

This study aims to elucidate the effect of ARHGAP9 on lung adenocarcinoma (LUAD) metastasis, and preliminarily explore its molecular mechanism. As a result, we found that ARHGAP9 was downregulated and correlated with poor prognosis of LUAD. ARHGAP9 knockdown promoted LUAD cell proliferation, migration and invasion, inhibited cell apoptosis and reduced G0G1 cell cycle arrest, in contrast to the results of ARHGAP9 overexpression. Further RNA sequencing analysis demonstrated that ARHGAP9 knockdown in H1299 cells significantly reduced DKK2 (dickkopf related protein 2) expression. Silencing ARHGAP9 in H1299 cells while overexpressing DKK2, DKK2 reversed the promoted effects of ARHGAP9 knockdown on LUAD cell proliferation, migration and invasion. Meanwhile, the activity of Wnt/β-catenin signaling pathway was also reduced. Taken together, these data indicated that ARHGAP9 knockdown promoted LUAD metastasis by activating Wnt/β-catenin signaling pathway via suppressing DKK2. This may provide a new strategy for LUAD treatment.     

miR-9-5p靶向Ambra1促进舌癌细胞增殖

miRNAs在肿瘤中异常表达,且与肿瘤的发生发展密切相关。目前发现,miR-9-5p在肿瘤中可能发挥原癌或抑癌效应,功能尚未完全阐述清楚。本文拟探讨miR-9-5p在舌癌中的作用。前期研究中收集10例舌癌组织及配对的癌旁组织,实时荧光定量PCR技术检测后发现,miR-9-5p在舌癌组织中的表达量显著高于癌旁组织,且其在舌癌细胞中的表达量也明显高于正常舌上皮细胞。此外,在舌癌细胞Tca8113中过表达miR-9-5p显著增加细胞的增殖能力。生物信息学预测及双荧光素酶报告基因实验证实,miR-9-5p可直接结合在自噬/苄氯素1调节因子1（activating molecule in beclin1-regulated autophagy, Ambra1）的 3′-UTR区域,靶向抑制Ambra1表达。Western印迹结果证实过表达miR-9-5p降低Ambra1的表达,反之亦然。Ambra1在舌癌细胞中的表达量显著低于正常舌上皮细胞。BrdU实验证实在舌癌细胞SCC-25中过表达Ambra1可显著抑制其增殖能力;相反,使用siRNA技术沉默Ambra1能够显著促进Tca8113细胞的增殖。在干预miR-9-5p的细胞中同时干预Ambra1的表达,结果发现Ambra1可显著逆转miR-9-5p对舌癌细胞增殖的促进作用。总之,miR-9-5p在舌癌中可能发挥原癌基因样作用,通过直接靶向抑制Ambra1表达进而促进舌癌细胞发生增殖。     

The diagnostic and prognostic value of pseudogene SIGLEC17P in lung adenocarcinoma and a preliminary functional study

Among malignant tumors, lung adenocarcinoma (LUAD) is the leading cause of death worldwide. This study explored the diagnostic, prognostic value, and preliminary functional verification of sialic acid binding Ig like lectin 17, pseudogene (SIGLEC17P) in LUAD. Prognostic lncRNAs for LUAD were identified by The Cancer Genome Atlas and quantitative real-time PCR (qRT-PCR) was used to detect the expression of SIGLEC17P in LUAD and paracarcinoma tissues. Subsequently, lentiviral vectors were used to overexpress SIGLEC17P in A549 and H1299 cells. The effects of SIGLEC17P overexpression on the proliferation, migration, and invasiveness of LUAD cells (A549 and H1299) were evaluated by Cell Counting Kit-8, wound healing, and transwell migration assays, respectively. Bioinformatics analyses were performed to reveal the potential pathways in which SIGLEC17P is involved in LUAD. qRT-PCR results revealed low SIGLEC17P expression in LUAD tissues and a significant association with the N stage, T stage, and tumor node metastasis stage. Furthermore, the receiver operating characteristic curve demonstrated a reliable diagnostic value. The proliferation, migration, and invasion of LUAD cells were inhibited by overexpression of SIGLEC17P. Bioinformatics analyses suggested that SIGLEC17P might exert antioncogenic effects in LUAD through the mir-20-3p/ADH1B or mir-4476-5p/DPYSL axis. In summary, our results revealed that SIGLEC17P acts as a prognostic biomarker, independent prognostic factor, and potential therapeutic target for patients with LUAD.     

MiR‐34b‐3p represses cell proliferation,cell cycle progression and cell apoptosis in non‐small‐cell lung cancer (NSCLC) by targeting CDK4

Lung cancer is the most common incident cancer, with a high mortality worldwide, and non‐small‐cell lung cancer (NSCLC) accounts for approximately 85% of cases. Numerous studies have shown that the aberrant expression of microRNAs (miRNAs) is associated with the development and progression of cancers. However, the clinical significance and biological roles of most miRNAs in NSCLC remain elusive. In this study, we identified a novel miRNA, miR‐34b‐3p, that suppressed NSCLC cell growth and investigated the underlying mechanism. miR‐34b‐3p was down‐regulated in both NSCLC tumour tissues and lung cancer cell lines (H1299 and A549). The overexpression of miR‐34b‐3p suppressed lung cancer cell (H1299 and A549) growth, including proliferation inhibition, cell cycle arrest and increased apoptosis. Furthermore, luciferase reporter assays confirmed that miR‐34b‐3p could bind to the cyclin‐dependent kinase 4 (CDK4) mRNA 3′‐untranslated region (3′‐UTR) to suppress the expression of CDK4 in NSCLC cells. H1299 and A549 cell proliferation inhibition is mediated by cell cycle arrest and apoptosis with CDK4 interference. Moreover, CDK4 overexpression effectively reversed miR‐34‐3p‐repressed NSCLC cell growth. In conclusion, our findings reveal that miR‐34b‐3p might function as a tumour suppressor in NSCLC by targeting CDK4 and that miR‐34b‐3p may, therefore, serve as a biomarker for the diagnosis and treatment of NSCLC.     

Dichloroacetate alters Warburg metabolism,inhibits cell growth,and increases the X-ray sensitivity of human A549 and H1299 NSC lung cancer cells

We investigated whether altering Warburg metabolism (aerobic glycolysis) by treatment with the metabolic agent dichloroacetate (DCA) could increase the X-ray-induced cell killing of the radiation-resistant human non-small-cell lung cancer (NSCLC) cell lines A549 and H1299. Treatment with 50 mM DCA decreased lactate production and glucose consumption in both A549 and H1299, clear indications of attenuated aerobic glycolysis. In addition, we found that DCA treatment also slowed cell growth, increased population-doubling time, and altered cell cycle distribution. Furthermore, we report that treatment with 50 mM DCA significantly increased single and fractionated X-ray-induced cell killing of A549 and H1299 cells. Assay of DNA double-strand break repair by neutral comet assays demonstrated that DCA inhibited both the fast and the slow kinetics of X-ray-induced DSB repair in both A549 and H1299 NSCL cancer cells. Taken together the data suggest a correlation between an attenuated aerobic glycolysis and enhanced cytotoxicity and radiation-induced cell killing in radiation-resistant NSCLC cells.     

Silencing lncRNA DUXAP8 inhibits lung adenocarcinoma progression by targeting miR-26b-5p

Lung adenocarcinoma (LUAD), a common type of lung cancer, has become a popularly aggressive cancer. Long noncoding RNAs (lncRNAs) play a critical role in the pathogenesis of human cancers, while the function of double homeobox A pseudogene 8 (DUXAP8) in LUAD remains to be fully inquired. Therefore, our study was conducted to elucidate the DUXAP8 expression in LUAD and its mechanism on the biological features of LUAD cells. Loss-of-function experiments were performed to assess the function of DUXAP8 proliferation and apoptosis of H1975 and A549 cells. Functionally, silencing DUXAP8 inhibited proliferation and induced apoptosis of LUAD cells. Mechanistically, further correlation assay indicated a negative association between miR-26b-5p and DUXAP8 expression. Subsequently, we testified that DUXAP8 exerted its role in the progression and development of LUAD through targeting miR-26b-5p. In summary, our results elucidated that that DUXAP8 promoted tumor progression in LUAD by targeting miR-26b-5p, which provide a novel therapeutic target for diagnosis and therapy of LUAD.